Overview

A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Status:
Approved for marketing

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

This is an open-label, non-comparative, multicenter, expanded access study of Vismodegib (GDC-0449) in patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC (mBCC) who are otherwise without satisfactory treatment options.

Details

Lead Sponsor:

Genentech, Inc.